KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
16.43
+0.03 (0.18%)
Dec 5, 2025, 4:00 PM EST - Market closed
KalVista Pharmaceuticals Revenue
KalVista Pharmaceuticals had revenue of $13.69M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $1.43M.
Revenue (ttm)
$1.43M
Revenue Growth
n/a
P/S Ratio
582.38
Revenue / Employee
$5,281
Employees
270
Market Cap
830.48M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
KALV News
- 11 days ago - KalVista Pharmaceuticals, Inc. (KALV) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 24 days ago - KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results - Business Wire
- 4 weeks ago - KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting - Business Wire
- 4 weeks ago - KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - Business Wire
- 4 weeks ago - KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025 - Business Wire
- 5 weeks ago - KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting - Business Wire
- 2 months ago - KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe - Business Wire